SupelMIP™ SPE-Amphetamines improves detection limits up to one hundred times compared with existing SPE phases on the market.
MIP Technologies AB and Supelco, a division of Sigma-Aldrich Corporation, have announced the launch of a new SupelMIP™ product for the selective extraction of amphetamine and related drugs.
A simple, fast, selective and highly sensitive SPE product has been developed for trace level determinations in forensic, toxicological and pharmaceutical testing. The SPE phase has been evaluated for:
- Amphetamine
- Methamphetamine
- Phentermine
- MDA
- MDMA
- MDEA
The product is currently being tested at the hospital laboratory in Ängelholm, Sweden. This laboratory is accredited for drug screening in workplaces and schools as well as being a confirmative testing reference site for the southern part of Sweden.
“This new SPE phase provides added value to the customers by being efficiently class-selective and allowing for lower limits of quantitation for the confirmation of this common drug of abuse,” - An Trinh, Product Manager, Supelco.